Bio partnering

They are building a diversified portfolio of innovative life science companies at various stages of clinical development, that improve the quality of life for patients and maximize benefit to their society.
By bringing strategic collaborators and smart investments, they support their drug development efforts through clinical trials to market entry.
Their biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.

Fund information

Investment areas

They share R&D risks of clinical development programs and provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, neurology, rare disease, rheumatology, musculoskeletal, immunology markets. They welcome projects seeking involvement of IAG’ expert team and advisors to bring additional value and increase chances of success for their portfolio companies. Should a portfolio company aim to seek a non-diluting funds, they are able to provide support including expertise of their academic partners to access national and international funds.

Other information

They are interested to discuss Development of clinical stage assets IP acquisition from the academic partners and biotech companies Investment partnerships Strategic collaborations.

Ways of communication
https://www.ia-grp.com/trial-solutions/bio-partnering

contact@ia-grp.com T (US): + 1 267 857 8638 T (UK): +44 203 821 1562